AU2004308378B2 - Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent - Google Patents

Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent Download PDF

Info

Publication number
AU2004308378B2
AU2004308378B2 AU2004308378A AU2004308378A AU2004308378B2 AU 2004308378 B2 AU2004308378 B2 AU 2004308378B2 AU 2004308378 A AU2004308378 A AU 2004308378A AU 2004308378 A AU2004308378 A AU 2004308378A AU 2004308378 B2 AU2004308378 B2 AU 2004308378B2
Authority
AU
Australia
Prior art keywords
response
biological
tissue
inhibiting agent
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004308378A
Other languages
English (en)
Other versions
AU2004308378A1 (en
Inventor
Allan L. Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegeneRx Biopharmaceuticals Inc
Original Assignee
RegeneRx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegeneRx Biopharmaceuticals Inc filed Critical RegeneRx Biopharmaceuticals Inc
Publication of AU2004308378A1 publication Critical patent/AU2004308378A1/en
Application granted granted Critical
Publication of AU2004308378B2 publication Critical patent/AU2004308378B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2004308378A 2003-12-22 2004-12-22 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent Ceased AU2004308378B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53089303P 2003-12-22 2003-12-22
US60/530,893 2003-12-22
PCT/US2004/042993 WO2005062864A2 (en) 2003-12-22 2004-12-22 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent

Publications (2)

Publication Number Publication Date
AU2004308378A1 AU2004308378A1 (en) 2005-07-14
AU2004308378B2 true AU2004308378B2 (en) 2010-05-13

Family

ID=34738610

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004308378A Ceased AU2004308378B2 (en) 2003-12-22 2004-12-22 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent

Country Status (7)

Country Link
US (1) US20090053194A1 (enExample)
EP (1) EP1706136A4 (enExample)
JP (1) JP2007521336A (enExample)
CN (1) CN1897965A (enExample)
AU (1) AU2004308378B2 (enExample)
CA (1) CA2550833A1 (enExample)
WO (1) WO2005062864A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1755661T3 (da) * 2004-05-12 2014-06-16 Brigham & Womens Hospital Gelsolin til anvendelse til behandling af infektioner
WO2007109056A2 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
WO2008134727A1 (en) * 2007-04-30 2008-11-06 The Board Of Regents Of The University Of Texas System Methods and compositions for treatment of reperfusion injury and other cardiac conditions
RU2364396C2 (ru) * 2007-11-07 2009-08-20 ФГУН "Нижегородский научно-исследовательский институт гигиены и профессиональной патологии" Роспотребнадзора Способ профилактики и коррекции иммунных нарушений, вызываемых токсическими веществами
ES2531827T3 (es) 2008-01-25 2015-03-20 The General Hospital Corporation Usos terapéuticos de gelsolina en insuficiencia renal
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
US20230025377A1 (en) * 2020-02-13 2023-01-26 HLB Therapeutics Co., Ltd. Compositions and methods for treating or preventing pruritus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049883A2 (en) * 1998-03-28 1999-10-07 The University Court Of The University Of Glasgow Oxidized thymosin beta 4
WO2000006190A1 (en) * 1998-07-30 2000-02-10 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health THYMOSIN β4 PROMOTES WOUND REPAIR
WO2001096527A2 (en) * 2000-06-14 2001-12-20 Chanda Zaveri Peptides with physiological activity
WO2003086449A1 (en) * 2002-04-12 2003-10-23 Yale University ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN β 4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525988A (ja) * 2001-05-17 2004-08-26 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４を用いる表皮水疱症（ＥｐｉｄｅｒｍｏｌｙｓｉｓＢｕｌｌｏｓａ）の治療
US9056087B2 (en) * 2001-08-29 2015-06-16 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049883A2 (en) * 1998-03-28 1999-10-07 The University Court Of The University Of Glasgow Oxidized thymosin beta 4
WO2000006190A1 (en) * 1998-07-30 2000-02-10 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health THYMOSIN β4 PROMOTES WOUND REPAIR
US20030060405A1 (en) * 1998-07-30 2003-03-27 Kleinman Hynda K. Compositions and methods for promoting wound healing and tissue repair
WO2001096527A2 (en) * 2000-06-14 2001-12-20 Chanda Zaveri Peptides with physiological activity
WO2003086449A1 (en) * 2002-04-12 2003-10-23 Yale University ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN β 4

Also Published As

Publication number Publication date
WO2005062864A2 (en) 2005-07-14
JP2007521336A (ja) 2007-08-02
AU2004308378A1 (en) 2005-07-14
CN1897965A (zh) 2007-01-17
EP1706136A4 (en) 2009-09-16
EP1706136A2 (en) 2006-10-04
CA2550833A1 (en) 2005-07-14
US20090053194A1 (en) 2009-02-26
WO2005062864A3 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
AU2008261127A1 (en) Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta 4 (TBeta4), Analogues, Isoforms and Other Derivatives
AU2004308378B2 (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
JP2009046502A (ja) 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用
AU2002255736A1 (en) Methods of Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
US8716215B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
US20110020449A1 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
JP2007521336A5 (enExample)
AU2004257868A1 (en) Treatment or prevention of damage due to radiation exposure
US20080051348A1 (en) Treatment of infections and other disorders
US20080096817A1 (en) METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU2002213513A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
US20040067227A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
MXPA06006849A (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
KR20070019668A (ko) 반응성 화학물질 또는 생물학적 물질 또는 독성 물질에대한 생물학적 또는 면역학적 반응들의 치료 또는 예방방법
WO2006076255A2 (en) Method of treating or preventing microbial eye infection
WO2005087805A1 (en) Treating or preventing extracellular matrix build-up
WO2006076254A2 (en) Method of treating or preventing respiratory microbial infection of respiratory tissue

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired